{"id":"https://openalex.org/W50056423","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.3049","title":"Safety and tolerability of AZD2171, a highly potent VEGFR inhibitor, in patients with advanced prostate adenocarcinoma","display_name":"Safety and tolerability of AZD2171, a highly potent VEGFR inhibitor, in patients with advanced prostate adenocarcinoma","publication_year":2005,"publication_date":"2005-06-01","ids":{"openalex":"https://openalex.org/W50056423","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.3049","mag":"50056423"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2005.23.16_suppl.3049","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.3049","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.3049","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5012804612","display_name":"Charles J. Ryan","orcid":"https://orcid.org/0000-0002-2081-3557","observed_orcids":["https://orcid.org/0000-0002-2081-3557"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Ryan","raw_affiliation_strings":["UCSF, San Francisco, CA; Univ of Chicago, Chicago, IL; Vanderbilt Univ, Nashville, TN; AstraZeneca, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCSF, San Francisco, CA; Univ of Chicago, Chicago, IL; Vanderbilt Univ, Nashville, TN; AstraZeneca, Wilmington, DE","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I200719446","https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088131964","display_name":"Walter Michael Stadler","orcid":"https://orcid.org/0000-0002-0435-2527","observed_orcids":["https://orcid.org/0000-0002-0435-2527"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"W. M. Stadler","raw_affiliation_strings":["UCSF, San Francisco, CA; Univ of Chicago, Chicago, IL; Vanderbilt Univ, Nashville, TN; AstraZeneca, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCSF, San Francisco, CA; Univ of Chicago, Chicago, IL; Vanderbilt Univ, Nashville, TN; AstraZeneca, Wilmington, DE","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I200719446","https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040850986","display_name":"Bruce J. Roth","orcid":"https://orcid.org/0000-0002-9333-571X","observed_orcids":["https://orcid.org/0000-0002-9333-571X"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"B. J. Roth","raw_affiliation_strings":["UCSF, San Francisco, CA; Univ of Chicago, Chicago, IL; Vanderbilt Univ, Nashville, TN; AstraZeneca, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCSF, San Francisco, CA; Univ of Chicago, Chicago, IL; Vanderbilt Univ, Nashville, TN; AstraZeneca, Wilmington, DE","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I200719446","https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000783146","display_name":"T. A. Puchalski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"T. A. Puchalski","raw_affiliation_strings":["UCSF, San Francisco, CA; Univ of Chicago, Chicago, IL; Vanderbilt Univ, Nashville, TN; AstraZeneca, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCSF, San Francisco, CA; Univ of Chicago, Chicago, IL; Vanderbilt Univ, Nashville, TN; AstraZeneca, Wilmington, DE","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I200719446","https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048598383","display_name":"Maria T. Koehler","orcid":"https://orcid.org/0000-0002-4477-9621","observed_orcids":["https://orcid.org/0000-0002-4477-9621"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Koehler","raw_affiliation_strings":["UCSF, San Francisco, CA; Univ of Chicago, Chicago, IL; Vanderbilt Univ, Nashville, TN; AstraZeneca, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCSF, San Francisco, CA; Univ of Chicago, Chicago, IL; Vanderbilt Univ, Nashville, TN; AstraZeneca, Wilmington, DE","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I200719446","https://openalex.org/I40347166"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5007578304","display_name":"Eric Jay Small","orcid":"https://orcid.org/0000-0003-3191-6268","observed_orcids":["https://orcid.org/0000-0003-3191-6268"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E. J. Small","raw_affiliation_strings":["UCSF, San Francisco, CA; Univ of Chicago, Chicago, IL; Vanderbilt Univ, Nashville, TN; AstraZeneca, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCSF, San Francisco, CA; Univ of Chicago, Chicago, IL; Vanderbilt Univ, Nashville, TN; AstraZeneca, Wilmington, DE","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I200719446","https://openalex.org/I40347166"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"23","issue":"16_suppl","first_page":"3049","last_page":"3049"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9804999828338623,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9804999828338623,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.01590000092983246,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vegfr-2-inhibitors","display_name":"VEGFR-2 inhibitors","score":0.8119999766349792},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7910000085830688},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7649999856948853},{"id":"https://openalex.org/keywords/anti-angiogenic-therapy","display_name":"anti-angiogenic therapy","score":0.8109999895095825},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8109999895095825},{"id":"https://openalex.org/keywords/vascular-endothelial-growth-factor","display_name":"vascular endothelial growth factor","score":0.6570000052452087},{"id":"https://openalex.org/keywords/oral-tyrosine-kinase-inhibitor","display_name":"oral tyrosine kinase inhibitor","score":0.765999972820282},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6159999966621399},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6430000066757202},{"id":"https://openalex.org/keywords/hematuria","display_name":"hematuria","score":0.7580000162124634},{"id":"https://openalex.org/keywords/transient-ischemic-attack","display_name":"transient ischemic attack","score":0.9419999718666077},{"id":"https://openalex.org/keywords/fatigue","display_name":"fatigue","score":0.6150000095367432},{"id":"https://openalex.org/keywords/hormone-therapy","display_name":"hormone therapy","score":0.48399999737739563}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.9064517617225647},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8914240598678589},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.72208172082901},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.595382034778595},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5885279774665833},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5624034404754639},{"id":"https://openalex.org/C2777025900","wikidata":"https://www.wikidata.org/wiki/Q29725","display_name":"Vascular endothelial growth factor","level":3,"score":0.495517373085022},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.481135755777359},{"id":"https://openalex.org/C2781182431","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Adenocarcinoma","level":3,"score":0.4556252956390381},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4484265148639679},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.4458487927913666},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.43136662244796753},{"id":"https://openalex.org/C2776235491","wikidata":"https://www.wikidata.org/wiki/Q9625","display_name":"Prostate","level":3,"score":0.42357051372528076},{"id":"https://openalex.org/C2778311097","wikidata":"https://www.wikidata.org/wiki/Q5903784","display_name":"Hormonal therapy","level":4,"score":0.4106194078922272},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3778078556060791},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.325738787651062},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2834051251411438},{"id":"https://openalex.org/C167734588","wikidata":"https://www.wikidata.org/wiki/Q4356503","display_name":"VEGF receptors","level":2,"score":0.13721010088920593}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2005.23.16_suppl.3049","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.3049","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.3049","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2591385705","https://openalex.org/W2137758263","https://openalex.org/W2084863129","https://openalex.org/W2605007591","https://openalex.org/W2268195585","https://openalex.org/W3009296135","https://openalex.org/W2339800992","https://openalex.org/W2228204672","https://openalex.org/W2534735228","https://openalex.org/W1954248775"],"abstract_inverted_index":{"3049":[0],"Background:":[1],"Vascular":[2],"endothelial":[3],"growth":[4],"factor-A":[5],"(VEGF)":[6],"is":[7,35,64,312],"a":[8,29,36,56],"key":[9],"factor":[10],"involved":[11],"in":[12,55,92,117,198,217,236,313,332],"tumor":[13],"blood":[14],"vessel":[15],"formation,":[16],"and":[17,88,171,212,235,246,280,306],"high":[18],"levels":[19],"of":[20,31,42,58,68,75,90,109,157,244,270,302],"VEGF":[21,43],"expression":[22],"are":[23,222],"associated":[24],"with":[25,66,94,194,228,240,264,334],"poor":[26],"prognosis":[27],"for":[28,130],"range":[30,57],"solid":[32],"malignancies.":[33],"AZD2171":[34,49,91,114,153,324],"highly":[37],"potent,":[38],"orally":[39],"available":[40,223,274],"inhibitor":[41],"receptor-2":[44],"(VEGFR-2)":[45],"tyrosine":[46],"kinase":[47],"activity.":[48],"has":[50,298],"shown":[51],"broad-spectrum":[52],"antitumor":[53],"activity":[54],"histologically":[59,124],"diverse":[60],"xenograft":[61],"models,":[62],"which":[63,131],"consistent":[65],"inhibition":[67],"VEGFR-2":[69],"signaling.":[70],"Methods:":[71],"The":[72,273],"primary":[73],"objective":[74,100,289],"this":[76,317],"Phase":[77],"I":[78],"multicenter,":[79],"open-label,":[80],"dose-escalation":[81],"trial":[82],"was":[83,101,325],"to":[84,102,254,261,295],"assess":[85,103],"the":[86,104,181,207,252,320],"safety":[87],"tolerability":[89],"patients":[93,122,150,226,238,333],"advanced":[95,335],"prostate":[96,128,336],"adenocarcinoma.":[97],"A":[98],"secondary":[99],"steady-state":[105],"pharmacokinetic":[106],"(PK)":[107],"profile":[108],"AZD2171.":[110],"Patients":[111],"received":[112,134,152],"oral":[113],"once":[115],"daily":[116,242],"21-day":[118],"treatment":[119,154],"cycles.":[120],"Eligible":[121],"had":[123,133],"or":[125,288,341,344],"cytologically":[126],"confirmed":[127],"adenocarcinoma,":[129],"they":[132],"previous":[135,143],"hormonal":[136],"therapy":[137],"and/or":[138],"no":[139,281,286],"more":[140,199],"than":[141,200],"one":[142,201,218],"chemotherapy":[144],"regimen.":[145],"Results:":[146],"To":[147,284],"date,":[148,285],"18":[149],"have":[151,291],"at":[155,328],"doses":[156,178,230,243,329],"1,":[158],"2.5,":[159],"5,":[160],"10":[161],"(all":[162,190],"n":[163],"=":[164,169,175,204],"3),":[165],"20":[166,208,309],"mg":[167,173,209,297,310],"(n":[168,174,203],"4)":[170],"30":[172,296],"2).":[176],"At":[177],"\u226410":[179,330],"mg,":[180,234],"nine":[182],"adverse":[183],"events":[184],"(AEs)":[185],"reported":[186,216],"were":[187,214],"generally":[188],"mild":[189],"CTCAE":[191],"grade":[192],"1),":[193],"only":[195],"fatigue":[196],"occurring":[197],"patient":[202],"3).":[205],"In":[206,316],"cohort,":[210],"TIA":[211],"hematuria":[213],"each":[215],"patient.":[219],"PK":[220,275,279],"data":[221,276],"from":[224,232,259],"eight":[225],"treated":[227,239],"single":[229],"ranging":[231],"1\u20135":[233],"six":[237],"multiple":[241],"1":[245],"2.5":[247],"mg.":[248],"After":[249],"single-dose":[250],"administration,":[251],"time":[253],"maximal":[255],"plasma":[256],"concentration":[257],"ranged":[258],"2":[260],"3":[262],"hours,":[263],"an":[265,307],"arithmetic":[266],"mean":[267],"effective":[268],"half-life":[269],"17.9":[271],"hours.":[272],"suggest":[277],"linear":[278],"time-dependent":[282],"changes.":[283],"serologic":[287],"responses":[290],"been":[292,299],"observed.":[293],"Accrual":[294],"suspended":[300],"because":[301],"suspected":[303],"dose-limiting":[304],"toxicities,":[305],"additional":[308],"cohort":[311],"progress.":[314],"Conclusions:":[315],"ongoing":[318],"study,":[319],"novel":[321],"antiangiogenic":[322],"agent":[323],"well":[326],"tolerated":[327],"mg/day":[331],"cancer.":[337],"Author":[338],"Disclosure":[339],"Employment":[340],"Leadership":[342],"Consultant":[343],"Advisory":[345],"Role":[346],"Stock":[347],"Ownership":[348],"Honoraria":[349],"Research":[350],"Funding":[351],"Expert":[352],"Testimony":[353],"Other":[354],"Remuneration":[355],"AstraZeneca":[356,357]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-06-24T00:00:00"}